Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Radiation Oncology
Published in: Radiation Oncology 1/2013

Open Access 01-12-2013 | Research

Prospective evaluation of quality of life 54 months after high-dose intensity-modulated radiotherapy for localized prostate cancer

Authors: Aurore Goineau, Virginie Marchand, Jérome Rigaud, Sylvain Bourdin, Emmanuel Rio, Loic Campion, Angélique Bonnaud-Antignac, Marc-André Mahé, Stéphane Supiot

Published in: Radiation Oncology | Issue 1/2013

Login to get access

Abstract

Objective

To determine late toxicity and quality of life (QoL) in patients with localized prostate cancer after high-dose intensity-modulated radiotherapy (IMRT).

Patient and methods

This was a prospective study in patients with localized prostate adenocarcinoma who had been treated by IMRT (76 Gy) between February and November 2006. Physicians scored acute and late toxicity using the Common Terminology Criteria for Adverse Events (version 3.0). Patients completed cancer and prostate-specific QoL questionnaires (EORTC QLQ-C30 and QLQ-PR25) before IMRT (baseline) and at 2, 6, 18 and 54 months.

Result

Data were available for 38 patients (median age, 73 years) (18% low risk; 60% intermediate risk; 32% high risk). The incidence of urinary and gastrointestinal toxicity was respectively: immediately post IMRT: 36.8% and 23.7% (grade 1), 5.3% and 5.3% (grade 2), 2.6% and 0% (grade 3); at 18 months: 23.7% and 10.3% (grade 1), 26.3% and 13.2% (grade 2), 0% and 2.6% (grade 3); at 54 months: 34.2% and 23.7% (grade 1), 5.3% and 15.8% (grade 2), 5.3% and 0% (grade 3). At 54 months, significant worsening was reported by patients for 11/19 QoL items but the worsening was clinically relevant (>10 points) for 7 items only: physical, role as well as social functioning, fatigue, pain, dyspnoea and constipation. There was no significant difference between 54-month and baseline QoL scores for global health, gastrointestinal symptoms, treatment-related symptoms and sexual function. However, there was significant - but clinically non-relevant (<10 points) - worsening of urinary symptom.

Conclusion

High-dose IMRT to the prostate with accurate patient positioning did not induce any clinically relevant worsening in late urinary and gastrointestinal QoL at 54 months. Impaired physical and role functioning may be related to age and comorbidities.
Appendix
Available only for authorised users
Literature
1.
D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998, 280: 969-974. 10.1001/jama.280.11.969CrossRefPubMed
2.
Hoskin PJ, Rojas AM, Bownes PJ, Lowe GJ, Ostler PJ, Bryant L: Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol 2012, 103: 217-222. 10.1016/j.radonc.2012.01.007CrossRefPubMed
3.
Martin JM, Supiot S, Berthold DR: Pharmacotherapeutic management of locally advanced prostate cancer: current status. Drugs 2011, 71: 1019-1041. 10.2165/11591500-000000000-00000CrossRefPubMed
4.
Lisbona A, Averbeck D, Supiot S, Delpon G, Ali D, Vinas F, Diana C, Murariu C, Lagrange J-L: IMRT combined to IGRT: increase of the irradiated volume. Consequences? Cancer Radiother 2010, 14: 563-570. 10.1016/j.canrad.2010.07.227CrossRefPubMed
5.
Crehange G, Mirjolet C, Gauthier M, Martin E, Truc G, Peignaux-Casasnovas K, Azelie C, Bonnetain F, Naudy S, Maingon P: Clinical impact of margin reduction on late toxicity and short-term biochemical control for patients treated with daily on-line image guided IMRT for prostate cancer. Radiother Oncol 2012, 103: 244-246. 10.1016/j.radonc.2011.10.025CrossRefPubMed
6.
Pollack A, Zagars GK, Smith LG, Lee JJ, Von Eschenbach AC, Antolak JA, Starkschall G, Rosen I: Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol 2000, 18: 3904-3911.PubMed
7.
Zietman AL, Bae K, Slater JD, Shipley WU, Efstathiou JA, Coen JJ, Bush DA, Lunt M, Spiegel DY, Skowronski R, Jabola BR, Rossi CJ: Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95–09. J Clin Oncol 2010, 28: 1106-1111. 10.1200/JCO.2009.25.8475CrossRefPubMedPubMedCentral
8.
Beckendorf V, Guerif S, Le Prisé E, Cosset J-M, Bougnoux A, Chauvet B, Salem N, Chapet O, Bourdain S, Bachaud J-M, Maingon P, Hannoun-Levi J-M, Malissard L, Simon J-M, Pommier P, Hay M, Dubray B, Lagrange J-L, Luporsi E, Bey P: 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys 2011, 80: 1056-1063. 10.1016/j.ijrobp.2010.03.049CrossRefPubMed
9.
Peeters STH, Heemsbergen WD, Koper PCM, Van Putten WLJ, Slot A, Dielwart MFH, Bonfrer JMG, Incrocci L, Lebesque JV: Dose–response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006, 24: 1990-1996. 10.1200/JCO.2005.05.2530CrossRefPubMed
10.
De Meerleer GO, Vakaet LA, De Gersem WR, De Wagter C, De Naeyer B, De Neve W: Radiotherapy of prostate cancer with or without intensity modulated beams: a planning comparison. Int J Radiat Oncol Biol Phys 2000, 47: 639-648. 10.1016/S0360-3016(00)00419-3CrossRefPubMed
11.
Peeters STH, Heemsbergen WD, Van Putten WLJ, Slot A, Tabak H, Mens JW, Lebesque JV, Koper PCM: Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys 2005, 61: 1019-1034. 10.1016/j.ijrobp.2004.07.715CrossRefPubMed
12.
Zelefsky MJ, Chan H, Hunt M, Yamada Y, Shippy AM, Amols H: Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 2006, 176: 1415-1419. 10.1016/j.juro.2006.06.002CrossRefPubMed
13.
Zelefsky MJ, Levin EJ, Hunt M, Yamada Y, Shippy AM, Jackson A, Amols HI: Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008, 70: 1124-1129. 10.1016/j.ijrobp.2007.11.044CrossRefPubMed
14.
Niezgoda HE, Pater JL: A validation study of the domains of the core EORTC quality of life questionnaire. Qual Life Res 1993, 2: 319-325. 10.1007/BF00449426CrossRefPubMed
15.
Ferrer M, Suárez JF, Guedea F, Fernández P, Macías V, Mariño A, Hervas A, Herruzo I, Ortiz MJ, Villavicencio H, Craven-Bratle J, Garin O, Aguiló F: Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2008, 72: 421-432. 10.1016/j.ijrobp.2007.12.024CrossRefPubMed
16.
Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, Lin X, Greenfield TK, Litwin MS, Saigal CS, Mahadevan A, Klein E, Kibel A, Pisters LL, Kuban D, Kaplan I, Wood D, Ciezki J, Shah N, Wei JT: Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008, 358: 1250-1261. 10.1056/NEJMoa074311CrossRefPubMed
17.
Litwin MS, Sadetsky N, Pasta DJ, Lubeck DP: Bowel function and bother after treatment for early stage prostate cancer: a longitudinal quality of life analysis from CaPSURE. J Urol 2004, 172: 515-519. 10.1097/01.ju.0000129236.56712.e7CrossRefPubMed
18.
Lips IM, Van Gils CH, Van der Heide UA, Kruger AEB, Van Vulpen M: Health-related quality of life 3 years after high-dose intensity-modulated radiotherapy with gold fiducial marker-based position verification. BJU Int 2009, 103: 762-767. 10.1111/j.1464-410X.2008.08117.xCrossRefPubMed
19.
Namiki S, Ishidoya S, Ito A, Tochigi T, Numata I, Narazaki K, Yamada S, Takai Y, Arai Y: Five-year follow-up of health-related quality of life after intensity-modulated radiation therapy for prostate cancer. Jpn J Clin Oncol 2009, 39: 732-738. 10.1093/jjco/hyp086CrossRefPubMed
20.
Odrazka K, Dolezel M, Vanasek J, Vaculikova M, Zouhar M, Sefrova J, Paluska P, Vosmik M, Kohlova T, Kolarova I, Macingova Z, Navratil P, Brodak M, Prosvic P: Time course of late rectal toxicity after radiation therapy for prostate cancer. Prostate Cancer Prostatic Dis 2010, 13: 138-143. 10.1038/pcan.2009.56CrossRefPubMed
21.
Sharma NK, Li T, Chen DY, Pollack A, Horwitz EM, Buyyounouski MK: Intensity-modulated radiotherapy reduces gastrointestinal toxicity in patients treated with androgen deprivation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 2011, 80: 437-444. 10.1016/j.ijrobp.2010.02.040CrossRefPubMed
22.
Marchand V, Bourdin S, Charbonnel C, Rio E, Munos C, Campion L, Bonnaud-Antignac A, Lisbona A, Mahé M-A, Supiot S: No impairment of quality of life 18 months after high-dose intensity-modulated radiotherapy for localized prostate cancer: a prospective study. Int J Radiat Oncol Biol Phys 2010, 77: 1053-1059. 10.1016/j.ijrobp.2009.06.024CrossRefPubMed
23.
Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, Scardino PT, Pearson JD: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997, 277: 1445-1451. 10.1001/jama.1997.03540420041027CrossRefPubMed
24.
Delpon G, Llagostera C, Le Blanc M, Rio E, Supiot S, Mahé M-A, Lisbona A: [Use of IGRT for prostate cancers (OBI-CBCT Varian, ExacTrac BrainLAB and MVCT TomoTherapy)]. Cancer Radiother 2009, 13: 399-407. 10.1016/j.canrad.2009.06.001CrossRefPubMed
25.
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, De Haes JC: The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993, 85: 365-376. 10.1093/jnci/85.5.365CrossRefPubMed
26.
Fayers P, Bottomley A: Quality Of life research within the EORTC-the EORTC QLQ-C30. European organisation for research and treatment of cancer. Eur J Cancer 2002,38(Suppl 4):S125-S133.CrossRefPubMed
27.
Osoba D, Rodrigues G, Myles J, Zee B, Pater J: Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998, 16: 139-144.PubMed
28.
Grant JD, Litwin MS, Kwan L, Lee SP, Steinberg ML, King CR: Does hormone therapy exacerbate the adverse effects of radiotherapy in men with prostate cancer? A quality of life study. J Urol 2011, 185: 1674-1680. 10.1016/j.juro.2010.12.092CrossRefPubMed
29.
Chen RC, Zhang Y, Chen M-H, McMahon E, Loffredo M, McPherson CP, Nguyen AU, Nguyen PL, D’Amico AV: Patient-reported quality of life during radiation treatment for localized prostate cancer: results from a prospective phase II trial. BJU Int 2012,110(11):1690-1695. 10.1111/j.1464-410X.2012.11117.xCrossRefPubMed
30.
Namiki S, Ishidoya S, Tochigi T, Kawamura S, Kuwahara M, Terai A, Yoshimura K, Numata I, Satoh M, Saito S, Takai Y, Yamada S, Arai Y: Health-related quality of life after intensity modulated radiation therapy for localized prostate cancer: comparison with conventional and conformal radiotherapy. Jpn J Clin Oncol 2006, 36: 224-230. 10.1093/jjco/hyl002CrossRefPubMed
31.
Odrazka K, Dolezel M, Vanasek J, Vaculikova M, Zouhar M, Sefrova J, Paluska P, Vosmik M, Kohlova T, Kolarova I, Navratil P, Brodak M, Prosvic P, Hoffmann P: Late toxicity after conformal and intensity-modulated radiation therapy for prostate cancer: impact of previous surgery for benign prostatic hyperplasia. Int J Urol 2010, 17: 784-790. 10.1111/j.1442-2042.2010.02592.xCrossRefPubMed
32.
Pederson AW, Fricano J, Correa D, Pelizzari CA, Liauw SL: Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity. Int J Radiat Oncol Biol Phys 2010,82(1):235-241.CrossRefPubMed
33.
Alicikus ZA, Yamada Y, Zhang Z, Pei X, Hunt M, Kollmeier M, Cox B, Zelefsky MJ: Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer. Cancer 2011, 117: 1429-1437. 10.1002/cncr.25467CrossRefPubMed
34.
Choo R, Long J, Gray R, Morton G, Gardner S, Danjoux C: Prospective survey of sexual function among patients with clinically localized prostate cancer referred for definitive radiotherapy and the impact of radiotherapy on sexual function. Support Care Cancer 2010, 18: 715-722. 10.1007/s00520-009-0675-6CrossRefPubMed
35.
Forbat L, White I, Marshall-Lucette S, Kelly D: Discussing the sexual consequences of treatment in radiotherapy and urology consultations with couples affected by prostate cancer. BJU Int 2011,109(1):98-103.CrossRefPubMed
36.
Vesprini D, Sia M, Lockwood G, Moseley D, Rosewall T, Bayley A, Bristow R, Chung P, Ménard C, Milosevic M, Warde P, Catton C: Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 2011, 81: e415-e421. 10.1016/j.ijrobp.2011.01.024CrossRefPubMed
37.
Denham JW, Wilcox C, Joseph D, Spry NA, Lamb DS, Tai K-H, Matthews J, Atkinson C, Turner S, Christie D, Gogna NK, Kenny L, Duchesne G, Delahunt B, McElduff P: Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial. Lancet Oncol 2012, 13: 1260-1270. 10.1016/S1470-2045(12)70423-0CrossRefPubMed
38.
Pinkawa M, Fischedick K, Asadpour B, Gagel B, Piroth MD, Eble MJ: Low-grade toxicity after conformal radiation therapy for prostate cancer–impact of bladder volume. Int J Radiat Oncol Biol Phys 2006, 64: 835-841. 10.1016/j.ijrobp.2005.09.003CrossRefPubMed
39.
Eade TN, Guo L, Forde E, Vaux K, Vass J, Hunt P, Kneebone A: Image-guided dose-escalated intensity-modulated radiation therapy for prostate cancer: treating to doses beyond 78 Gy. BJU Int 2011,109(11):1655-1660.CrossRefPubMed
Metadata
Title
Prospective evaluation of quality of life 54 months after high-dose intensity-modulated radiotherapy for localized prostate cancer
Authors
Aurore Goineau
Virginie Marchand
Jérome Rigaud
Sylvain Bourdin
Emmanuel Rio
Loic Campion
Angélique Bonnaud-Antignac
Marc-André Mahé
Stéphane Supiot
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2013
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/1748-717X-8-53

Other articles of this Issue 1/2013

Radiation Oncology 1/2013 Go to the issue

Research

Stereotactic body radiation therapy for the treatment of early-stage minimally invasive adenocarcinoma or adenocarcnioma in situ (formerly bronchioloalveolar carcinoma): a patterns of failure analysis

Research

Radiation-induced liver disease after stereotactic body radiotherapy for small hepatocellular carcinoma: clinical and dose-volumetric parameters

Research

Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years

Methodology

Three-dimensional conformal radiotherapy with concurrent chemotherapy for postoperative recurrence of esophageal squamous cell carcinoma: clinical efficacy and failure pattern

Research

High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma

Research

Clinical evaluation of multi-atlas based segmentation of lymph node regions in head and neck and prostate cancer patients